MISSISSIPPI LEGISLATURE
2026 Regular Session
To: Public Health and Human Services
By: Representatives Cockerham, Scott
AN ACT TO ESTABLISH THE RARE DISEASE TASK FORCE WITHIN THE MISSISSIPPI RARE DISEASE ADVISORY COUNCIL; TO PROVIDE THAT THE PURPOSE OF THE TASK FORCE IS TO IDENTIFY GAPS IN CARE, EVALUATE FUNDING AND INSURANCE COVERAGE PRACTICES, ADVISE POLICYMAKERS ON EVIDENCE-BASED SOLUTIONS, AND ENSURE FAIR, TIMELY, AND EQUITABLE ACCESS TO RARE DISEASE THERAPIES IN THIS STATE; TO PROVIDE FOR THE MEMBERSHIP, POWERS AND DUTIES OF THE TASK FORCE; TO PROTECT ACCESS TO RARE DISEASE THERAPIES BY PROHIBITING HEALTH INSURERS, HEALTH BENEFIT PLANS AND PHARMACY BENEFIT MANAGERS FROM EXCLUDING, REMOVING OR RECLASSIFYING A RARE DISEASE THERAPY THAT WOULD OTHERWISE BE COVERED UNDER A PLAN'S FORMULARY OR BENEFIT DESIGN FOR THE PURPOSE OR EFFECT OF OBTAINING, DIRECTING, OR RELYING UPON FINANCIAL ASSISTANCE FROM A MANUFACTURER, CHARITABLE ORGANIZATION, OR OTHER THIRD PARTY; TO PROVIDE FOR ENFORCEMENT, REPORTING, AND RULEMAKING AUTHORITY; TO AMEND SECTION 83-5-35, MISSISSIPPI CODE OF 1972, TO CONFORM TO THE PROVISIONS OF THIS ACT; AND FOR RELATED PURPOSES.
BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF MISSISSIPPI:
SECTION 1. Legislative findings and purpose. (1) The Legislature finds that rare diseases collectively affect a substantial number of residents of the State of Mississippi and frequently result in delayed diagnosis, limited treatment options, fragmented care delivery, and significant financial burdens for patients and their families. The Legislature further finds that certain insurance coverage practices, including the use of alternative funding programs, may improperly limit or delay access to medically necessary therapies for individuals living with rare diseases.
(2) The purpose of this act is to establish a coordinated, expert-driven Rare Disease Task Force to identify gaps in care, evaluate funding and insurance coverage practices, advise policymakers on evidence-based solutions, and ensure fair, timely, and equitable access to rare disease therapies in the State of Mississippi.
SECTION 2. Definitions. For the purposes of this act, the following terms shall be defined as provided in this section, unless the context clearly requires otherwise:
(a) "Rare disease" means a disease or condition affecting a small percentage of the population, including conditions designated under 21 USC Section 360bb or recognized as rare by nationally recognized medical authorities.
(b) "Council" means the Mississippi Rare Disease Advisory Council established under Section 41-145-3.
(c) "Task force" means the Rare Disease Task Force established under this act.
(d) "Alternative funding program" means any program or arrangement that relies on manufacturer assistance, charitable contributions, or other third-party financial aid in lieu of direct insurance coverage for a prescribed therapy.
SECTION 3. Establishment of the Rare Disease Task Force. The Rare Disease Task Force is established within the Mississippi Rare Disease Advisory Council. The Task Force shall serve as a coordinated, expert-driven advisory body to provide guidance and recommendations regarding health challenges, treatment access, insurance coverage practices, and funding considerations related to rare diseases in the State of Mississippi.
SECTION 4. Membership. (1) the task force shall be composed of members representing a broad range of professional expertise and lived experience, including but not limited to:
(a) Licensed clinicians with experience diagnosing or treating rare diseases;
(b) Medical or scientific researchers specializing in rare diseases;
(c) Individuals diagnosed with a rare disease;
(d) Family members or caregivers of individuals with rare diseases;
(e) Representatives of rare disease patient advocacy organizations; and
(f) Policymakers or designees with expertise in public health, insurance regulation or health finance.
(2) The task force shall consist of seven (7) members. The members of the task force shall be appointed as follows: One (1) member appointed by the Lieutenant Governor; one (1) member appointed by the Speaker of the House of Representatives; and three (3) members appointed by the Governor; all in accordance with procedures established by the council and consistent with state law. The council shall appoint one (1) member who is actively employed in the insurance industry at the time of appointment. The chairman of the council shall also be the chair of the task force.
(3) Members shall serve without compensation, but may be reimbursed for actual and necessary expenses, subject to the availability of funds.
SECTION 5. Powers and duties of the task force. The task force shall have the authority and responsibility to:
(a) Identify gaps in care, coverage limitations, workforce shortages, and systemic barriers affecting individuals with rare diseases in the State of Mississippi;
(b) Advise the Governor, Legislature, and relevant state agencies on evidence-based policy, regulatory, and funding recommendations to improve the quality, coordination, and accessibility of rare disease care;
(c) Review and evaluate alternative funding programs and insurance coverage practices impacting access to rare disease therapies and assess their fiscal, clinical, and equity implications; and
(d) Ensure that the perspectives and experiences of patients and caregivers are meaningfully represented and considered in all task force deliberations and recommendations.
SECTION 6. Coordination and oversight. (1) The Department of Insurance shall consult with the council and the task force to monitor emerging coverage barriers related to rare disease therapies.
(2) The Council may accept and review written complaints from patients, providers, or advocacy organizations regarding alternative funding practices and shall refer substantiated complaints to the Department of Insurance for investigation.
SECTION 7. Reporting requirements. (1) No later than December 1 of each year, the task force, in collaboration with the Department of Insurance, shall submit a written report to the Governor, the Lieutenant Governor, the Speaker of the House of Representatives, and the relevant legislative committees.
(2) The report shall include:
(a) A summary of task force activities and findings;
(b) Trends in rare disease therapy access and insurance coverage;
(c) The prevalence and impact of alternative funding programs in Mississippi; and
(d) Recommendations for legislative, regulatory, or administrative action.
SECTION 8. Insurance coverage integrity for rare disease therapies. (1) A health insurer, health benefit plan, or pharmacy benefit manager regulated by the Department of Insurance shall not:
(a) Exclude, remove, or reclassify a rare disease therapy that would otherwise be covered under a plan's formulary or benefit design for the purpose or effect of obtaining, directing, or relying upon financial assistance from a manufacturer, charitable organization, or other third party;
(b) Designate a rare disease therapy as "nonessential," "noncovered," or any similar classification intended to avoid the obligation to cover or reimburse for the therapy; or
(c) Condition, delay, or deny coverage of a prescribed rare disease therapy based on the availability or potential availability of third-party financial assistance.
(2) A rebuttable presumption of violation of this section shall exist if a health insurer, health benefit plan or pharmacy benefit manager removes a prescribed rare disease therapy from coverage and directs or refers an enrollee to an alternative funding program as a means of obtaining that therapy.
(3) The presumption may be rebutted only by clear and convincing evidence, submitted to the Department of Insurance, that the exclusion or reclassification was made solely for legitimate clinical reasons and not for the purpose or effect of shifting payment responsibility.
(4) Any violation of this section shall constitute an unfair or deceptive act or practice in the business of insurance under Mississippi law and shall be subject to all existing enforcement powers, remedies, and penalties of the Department of Insurance, including the authority to order reimbursement for out-of-pocket costs or delays in treatment.
SECTION 9. Rulemaking authority. The Department of Insurance may adopt rules and require plan filings necessary to implement this act, including documentation demonstrating compliance with formulary inclusion standards and reporting of any reclassification or exclusion of previously covered rare disease therapies.
SECTION 10. Section 83-5-35, Mississippi Code of 1972, is amended as follows:
83-5-35. The following are * * * defined as unfair methods of competition
and unfair and deceptive acts or practices in the business of insurance:
(a) Misrepresentations and false advertising of policy contracts. Making, issuing, circulating, or causing to be made, issued, or circulated, any estimate, illustration, circular, or statement misrepresenting the terms of any policy issued or to be issued, or the benefits or advantages promised thereby, or the dividends or share of the surplus to be received thereon; or making any false or misleading statement as to the dividends or share of surplus previously paid on similar policies; or making any misleading representation or any misrepresentation as to the financial condition of any insurer, or as to the legal reserve system upon which any life insurer operates; or using any name or title of any policy or class of policies misrepresenting the true nature thereof; or making any misrepresentation to any policyholder insured in any company for the purpose of inducing or tending to induce such policyholder to lapse, forfeit, or surrender his insurance.
(b) False information and advertising generally. Making, publishing, disseminating, circulating, or placing before the public, or causing, directly or indirectly, to be made, published, disseminated, circulated, or placed before the public, in a newspaper, magazine, or other publication, or in the form of a notice, circular, pamphlet, letter, or poster, or over any radio or television station, or in any other way, an advertisement, announcement, or statement containing any assertion, representation, or statement with respect to the business of insurance, or with respect to any person in the conduct of his insurance business, which is untrue, deceptive, or misleading.
(c) Defamation. Making, publishing, disseminating, or circulating, directly or indirectly, or aiding, abetting, or encouraging the making, publishing, disseminating, or circulating of any oral or written statement or any pamphlet, circular, article, or literature which is false and maliciously critical of or derogatory to the financial condition of an insurer, and which is calculated to injure any person engaged in the business of insurance.
(d) Boycott, coercion and intimidation. Entering into any agreement to commit, or by any concerted action committing, any act of boycott, coercion, or intimidation resulting in or tending to result in unreasonable restraint of, or monopoly in, the business of insurance.
(e) False financial statements. Filing with any supervisory or other public official, or making, publishing, disseminating, circulating, or delivering to any person, or placing before the public, or causing directly or indirectly to be made, published, disseminated, circulated, delivered to any person, or placed before the public, any false statement of financial condition of an insurer, with intent to deceive.
Making any false entry in any book, report, or statement of any insurer with intent to deceive any agent or examiner lawfully appointed to examine into its condition or into any of its affairs, or any public official to whom such insurer is required by law to report or file, or who has authority by law to examine into its condition or into any of its affairs, or, with like intent, willfully omitting to make a true entry of any material fact pertaining to the business of such insurer in any book, report, or statement of such insurer.
(f) Stock operations and insurance company advisory board contracts. Issuing or delivering, or permitting agents, officers, or employees to issue or deliver, agency company stock or other capital stock, or benefit certificates or shares in any corporation, or securities, or any special or any insurance company advisory board contracts or other contracts of any kind promising returns and profit as an inducement to insurance.
(g) Unfair discrimination. (i) Making or permitting any unfair discrimination between individuals of the same class and equal expectation of life in the rates charged for any contract of life insurance or of life annuity or in the dividends or other benefits payable thereon, or in any other of the terms and conditions of such contract.
(ii) Making or permitting any unfair discrimination between individuals of the same class and of essentially the same hazard in the amount of premium, policy fees, or rates charged for any policy or contract of accident or health insurance or in the benefits payable thereunder, or in any of the terms or conditions of such contract, or in any other manner whatever.
(iii) Any violation of Section 83-71-7, 83-71-57 or 83-71-107.
(h) Designation of agent, solicitor, or insurer. Requiring as a condition precedent to the purchase or the lending of money upon the security of real or personal property that any insurance covering such property or liability arising from the ownership, maintenance, or use thereof, to be procured by or on behalf of the vendee or by borrower in connection with such purchase or loan, be so procured through any particular person, agent, solicitor, or in any particular insurer.
This section shall not prevent the reasonable exercise by any such vendor or lender of his right to approve or disapprove the insurer selected to underwrite the insurance, and to determine the adequacy of the insurance offered.
(i) Any violation of Sections 83-3-33 and 83-3-121, Mississippi Code of 1972.
(j) Any violation of Section 8 of this act.
SECTION 11. This act shall take effect and be in force from and after July 1, 2026, except for Section 8, which shall take effect and be in force from and after January 1, 2027, and shall apply to all health insurers, health benefit plans and pharmacy benefit managers regulated by the Department of Insurance that are issued, renewed, or amended on or after that date.